Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2018 Jun 15;17(9):1859–1870. doi: 10.1158/1535-7163.MCT-17-1176

Figure 3. Effects of bromocriptine on the expression of DRD2 and cell signaling molecules.

Figure 3

(A) Upper panel: Western blot analysis of protein expression of DRD2 in C4-2 cells treated with 20 μM bromocriptine; Lower panel: Cells were pre-incubated with sulpiride (1 μM) for 1 h prior to bromocriptine treatment. (B) Western blot analysis of protein expression of survivin, PARP1 and caspase-3 in C4-2 cells treated with 20 μM bromocriptine for varying times. (C) Left: Western blot analysis of protein expression of cell cycle regulators in C4-2 cells treated with 20 μM bromocriptine for varying times; Right: Western blot analysis of p-MDM2(S166) and MDM2 in C4-2 cells treated with 20 μM bromocriptine for varying times. (D) Left: Western blot analysis of protein expression of key DRD2 downstream effectors in C4-2 cells treated with 20 μM bromocriptine for varying times; Right: Cells were pre-incubated with sulpiride (1 μM) for 1 h prior to bromocriptine treatment, then cell lysates were analyzed using Western blotting. (E) Left: Western blot analysis of protein expression of potential bromocriptine targets in C4-2 cells transfected with control or expression vector for GFP-tagged human DRD2 (48 h); Right: Western blot analysis of protein expression of potential bromocriptine targets in LNCaP cells transfected with a DRD2 shRNA or scramble control construct.